CJC-1295 vs HGH Therapy Mechanism: Research Application Comparison
Primary Mechanism Binds GHRH receptors on pituitary somatotrophs → upregulates endogenous GH synthesis and pulsatile release Exogenous bioidentical GH enters circulation directly → binds GH receptors on target tissues, bypassing pituitary CJC-1295 amplifies na
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Binds GHRH receptors on pituitary somatotrophs → upregulates endogenous GH synthesis and pulsatile release
- Exogenous bioidentical GH enters circulation directly → binds GH receptors on target tissues, bypassing pituitary
- CJC-1295 amplifies natural secretion rhythm; rhGH replaces it entirely
- Half-Life & Dosing
- 6–8 days (with DAC modification). Once weekly administration maintains effect
- 2.5–4 hours. Requires daily or twice-daily injections for sustained elevation
- Weekly dosing simplifies compliance; daily rhGH injections offer tighter pharmacokinetic control
- IGF-1 Elevation Pattern
- Pulsatile peaks (1.5–2.5× baseline). Maintains circadian variation
- Sustained elevation (2–4× baseline). Flattened across 24-hour cycle at therapeutic doses
- Pulsatile IGF-1 better preserves insulin sensitivity; sustained elevation accelerates tissue effects
- Feedback Loop Impact
- Preserves somatostatin-mediated inhibition. Pituitary function maintained
- Suppresses endogenous GH secretion via negative feedback. Pituitary atrophy over extended use
- CJC-1295 suitable for long-term protocols requiring preserved endogenous capacity
- Typical Research Dose Range
- 1–2 mg per week (split or single dose depending on protocol design)
- 0.3–0.6 mg/day for metabolic research; 2–4 IU/day (0.67–1.33 mg) for anabolic studies
- Dose comparison not 1:1. Mechanisms too different to equate directly
- Primary Use Case in Research
- Protocols requiring physiological GH rhythm preservation, long-term metabolic studies, anti-aging models
- Acute anabolic studies, GH deficiency replacement models, controlled IGF-1 elevation experiments
- Choose based on whether research design benefits from feedback preservation or pharmacokinetic precision